SABiosciences

SABiosciences

SABiosciences, a QIAGEN company. The Leader for Pathway and Disease Biology Research Products..

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round

N/A

Acquisition
Total Funding000k
Notes (0)
More about SABiosciences
Made with AI
Edit

SABiosciences Corporation, established in 1998, carved a niche in the biotechnology sector by developing tools for a systematic approach to biological research. The company was founded with the vision of merging hypothesis-driven and discovery-based research to accelerate advancements in life sciences.

A significant milestone in the company's history was its acquisition by QIAGEN N.V. in December 2009 for approximately $90 million in cash. This strategic move integrated SABiosciences' expertise in disease- and pathway-focused assay development with QIAGEN's global leadership in molecular biology. At the time of the acquisition, SABiosciences was based in Frederick, Maryland, and employed around 100 people. The president of SABiosciences during this transition was Li Shen.

The core of SABiosciences' business revolves around the design, development, and manufacturing of real-time PCR (Polymerase Chain Reaction) assay panels. Unlike conventional methods that study a single gene, SABiosciences pioneered pre-formatted panels that analyze the expression of all genes associated with a specific biological pathway or disease state in a single experiment. This allows researchers to understand how gene activity correlates with conditions like cancer, diabetes, and immune or cardiovascular disorders. Their product portfolio included over 100 different PCR Array panels for analyzing DNA, RNA, microRNA, and epigenetic targets. These tools serve a client base of academic researchers, as well as pharmaceutical and biotechnology companies, aiding in the discovery and validation of biomarkers for drug development and future diagnostics.

Revenue was generated through the sale of these pathway-focused kits and related products, which include gene array products and RNA interference tools. Following the acquisition, QIAGEN planned to establish the Frederick site as a Center of Excellence in biological content development, leveraging SABiosciences' bioinformatics capabilities to enhance its own diagnostic and pharmaceutical research offerings.

Keywords: PCR array, gene expression analysis, pathway analysis, biomarker discovery, molecular biology, life science research tools, real-time PCR, disease pathway analysis, drug discovery, RNA interference, diagnostics development, bioinformatics, assay panels, epigenetic analysis, molecular diagnostics, biotechnology, genomic research, cell function pathways, toxicology assays, stem cell research

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo